People taking GLP-1s are more than four times as likely to report nail detachment as similar patients with obesity or type 2 diabetes who don’t take the drugs, according to research presented Oct. 1 at the European Academy of Dermatology and Venereology Congress 2026 in Vienna.
The researchers said their work is the first controlled study of GLP-1s and nail health. They compared 575 GLP-1 users with a control group of 1,329 people across the U.S., France, Brazil and Mexico.
Three findings:
- 39% of GLP-1 users reported nail detachment vs. 9% of controls
- 46% reported nail discoloration vs. 17%
- 66% reported at least one nail disorder vs. 53%
The gaps held among participants who had lost weight, which suggests weight loss alone doesn’t explain them. About half of users said they had nail problems before starting treatment. However, even after the researchers adjusted for skin conditions and nutritional deficiencies, GLP-1 users still reported nail detachment and discoloration about two to three times as often.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” study author Charles Taïeb, MD, PhD, said in a Sept. 30 news release. “Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
The researchers are planning future studies to follow patients from the start of treatment, using standardized dermatological exams and biological monitoring to learn when the changes develop, why they occur and whether they’re reversible.
